Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) is pleased to announce that it has signed a licensing agreement with Isodiol International Inc., a leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of CBD consumer products, to provide a complementary suite of medical cannabis products to patients in Florida and Massachusetts.
“Liberty is proud to team up with Isodiol, a company renowned for its ability to process and extract high purity CBD on an industrial scale,” said George Scorsis, Director and CEO of Liberty. “We are committed to providing all our patients across Massachusetts and Florida with an extensive selection of medical cannabis and derivative products. Isodiol is a fantastic addition to our rapidly expanding portfolio of celebrated brands as we continue to execute on our aggressive growth strategy to roll out dispensary locations and product offerings across Florida and Massachusetts.”
The Isodiol branded products will be available for sale through Liberty’s Cannabis Education Centers. The Company continues to add an assortment of products and brands that allow Liberty to address the needs of all patients in a variety of forms. This exciting new product line will complement Liberty’s expanding lineup of brands to be offered to Florida and Massachusetts patients, including Aphria, Solei, Mary’s Medicinals and incredibles. The agreement with Isodiol allows Liberty to license and produce the following products:
- Isodiol’s BIOACTIVE CBD
- Isodiol’s CannaCeuticals
- Isodiol’s IsoDerm
- Isodiol’s IsoSport products
- Isodiol’s Rapid Cream
- Isodiol’s Rapid Patch
- Isodiol’s Pot-O-Coffee
“Isodiol is excited to partner with a company that is equally committed to bring health and wellness to consumers around the globe,” said CEO of Isodiol, Marcos Agramont. “Florida and Massachusetts will further expand the marketplace for Isodiol and we look forward to establishing a long-term partnership with Liberty with further expansion down the road.”
Possessing the unique ability to export its pharmaceuticals grade, natural hemp derived Cannabidiol (CBD) product technology anywhere in the world, Isodiol is prepared to meet the United States’ rapidly increasing demand for the active CBD substance working with a partner such as Liberty. This international distribution capability was secured on April 26, 2018, when Isodiol’s wholly owned subsidiary, BSPG Laboratories, LTD., received cGMP compliance status from United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA), for the manufacture of the active substance Cannabidiol using their proprietary technology.
The closing of this agreement is subject to receipt of all required approvals from the Florida Department of Health, Office of Medical Marijuana Use and the Commonwealth of Massachusetts, Medical Use of Marijuana Program or the Massachusetts Cannabis Control Commission.
About Liberty Health Sciences Inc.
Liberty Health Sciences Inc. is an investor and operator in the medical cannabis market, capitalizing on new and existing opportunities in U.S. states where medical cannabis is legal. Liberty’s stringent investment criteria for expansion maximizes returns to shareholders, while focusing on significant near- and mid-term opportunities. Liberty has an extensive background in highly regulated industries, with expertise in becoming a low-cost producer. Liberty leverages commercial greenhouse knowledge to deliver high-quality, clean and safe pharmaceutical grade cannabis to patients.
For more information, please visit libertyheathsciences.com
MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers